Literature DB >> 9512905

Impaired production of IL-12 in system lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE.

T F Liu1, B M Jones.   

Abstract

Interleukin 12 (IL-12) is a key cytokine in regulating type 1 or type 2 cytokine production and in determining the nature of immune responses. Our previous studies demonstrated that its production was significantly impaired in systemic lupus erythematosus (SLE) patients and this deficient IL-12 production was mainly mediated by excessive endogenous IL-10. The present study was designed to further reveal the relationships of in vitro IL-12 production with abnormalities of in vivo cytokine synthesis and disease activity in SLE. Experimental results showed that IL-12 production in vitro was inversely correlated with serum IL-10 level, anti-ds DNA antibody level and SLE disease activity index (DAI), but positively correlated with serum interferon gamma (IFN-gamma) level, with which serum IL-10 correlated negatively. Data also showed that serum IL-10 was significantly higher than that of controls and closely correlated with anti-ds DNA antibody level and SLEDAI. The study confirms that deficient IL-12 production in SLE patients is associated with in vivo abnormalities of cytokine production, especially with increased IL-10 production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512905     DOI: 10.1006/cyto.1997.0269

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  14 in total

1.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Immune complex-stimulated production of interleukin-12 in peripheral blood mononuclear cells is regulated by the complement system.

Authors:  A Tejde; L Mathsson; K N Ekdahl; B Nilsson; J Rönnelid
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 3.  Genetic regulation of serum cytokines in systemic lupus erythematosus.

Authors:  Silvia N Kariuki; Timothy B Niewold
Journal:  Transl Res       Date:  2009-09-25       Impact factor: 7.012

4.  Plasma interleukin-10 and interleukin-12 levels in patients with familial Mediterranean fever.

Authors:  Eren Erken; Huseyin T E Ozer; Ramazan Gunesacar
Journal:  Rheumatol Int       Date:  2006-01-06       Impact factor: 2.631

5.  Differential effect of IL10 and TNF{alpha} genotypes on determining susceptibility to discoid and systemic lupus erythematosus.

Authors:  A Suárez; P López; L Mozo; C Gutiérrez
Journal:  Ann Rheum Dis       Date:  2005-03-30       Impact factor: 19.103

6.  Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies.

Authors:  L Mathsson; E Ahlin; C Sjöwall; T Skogh; J Rönnelid
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 7.  Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus.

Authors:  Hui Peng; Wei Wang; Mo Zhou; Rui Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2013-05-25       Impact factor: 2.980

8.  Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis.

Authors:  M Tucci; L Lombardi; H B Richards; F Dammacco; F Silvestris
Journal:  Clin Exp Immunol       Date:  2008-09-15       Impact factor: 4.330

9.  Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus.

Authors:  C K Wong; C Y Ho; E K Li; L S Tam; C W K Lam
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

10.  Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile.

Authors:  Sana Al-Mutairi; Adel Al-Awadhi; Raj Raghupathy; Hanaa Al-Khawari; Prio Sada; Adeebah Al-Herz; Parvez Rawoot
Journal:  Rheumatol Int       Date:  2006-11-14       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.